Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | not yet recruiting | Phase 2 | 11 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06685458 | Constructing a Predictive Model for Differentiating Between Benign and Malignant Solid Pulmonary Nodules Based on Clinical and Imaging Features. | not yet recruiting | — | 320 | The Third Affiliated Hospital of Kunming Medical College.OTHER |
| 0 |
| Nov 12, 2024 |
| clinicaltrials |
| NCT06685653 | Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients | not yet recruiting | Early Phase 1 | 65 | Nanjing Tianyinshan HospitalOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT06680115 | Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 150 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681285 | Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)(CAR-RMEC) | not yet recruiting | Phase 2 | 51 | Hebei Medical University Fourth HospitalOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681636 | Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure(HPV9vxFSW) | not yet recruiting | Phase 2 | 300 | National Institute of Hygiene and Epidemiology, VietnamOTHER | 2 | Nov 8, 2024 | clinicaltrials |
| NCT06449417 | Aurora: a Human-centered Program for Breast Cancer Patients in Chile, Easing Neoadjuvant Chemotherapy's Effects(Aurora) | not yet recruiting | N/A | 30 | Pontificia Universidad Catolica de ChileOTHER | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06677762 | Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer | not yet recruiting | — | 55 | Ruijin HospitalOTHER | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06671717 | Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma | not yet recruiting | N/A | 25 | Peking University People's HospitalOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06407401 | Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer | not yet recruiting | Phase 3 | 399 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06662513 | Post Oesophagectomy Outcomes in a Single Regional Centre in Australia | not yet recruiting | — | 100 | Launceston General HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06672133 | Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC(RALLY) | not yet recruiting | Phase 3 | 524 | Jinming YuOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06672341 | Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation | not yet recruiting | — | 200 | Yulan RenOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06674330 | Using a Population Pharmacokinetic Model to Estimate the Dosage of Teicoplanin in Patients With Hematologic Malignancy or Critical Illness | not yet recruiting | — | 600 | National Taiwan University HospitalOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06674850 | Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia | not yet recruiting | — | 36 | Assiut UniversityOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06675656 | Predictive Role of Microbiome in Patients With Urothelial Carcinoma | not yet recruiting | — | 420 | IRCCS San RaffaeleOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06671249 | Comparing the Safety and Cosmetic Outcomes Between Laparoscopic Versus Traditional Open Breast-conserving Surgery | not yet recruiting | N/A | 184 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06672263 | A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia | not yet recruiting | Phase 1 | 120 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection(PREPAP) | not yet recruiting | Phase 1 / Phase 2 | 66 | MGB PharmaINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06646666 | ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT | not yet recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06661265 | Predictors of Acute Toxicity and Flap Failure After Adjuvant Treatment for Locally Advanced Head and Neck Cancer | not yet recruiting | — | 46 | IRCCS San RaffaeleOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06667583 | 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients | not yet recruiting | — | 40 | Assiut UniversityOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06668948 | The Prognostic Role of Fibrinogen to Albumin Ratio in Acute Leukemia Patients | not yet recruiting | — | 90 | Assiut UniversityOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06669078 | NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer(NALIRIFOX) | not yet recruiting | Phase 2 | 120 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06669143 | Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission | not yet recruiting | Phase 2 | 19 | Ruijin HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06669923 | Understanding Sugar-Sweetened Beverages (SSB) and Colorectal Cancer (CRC)(SSB and CRC) | not yet recruiting | N/A | 120 | University of VirginiaOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06670547 | Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography | not yet recruiting | — | 3,000 | Germans Trias i Pujol HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06665334 | To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery | not yet recruiting | Phase 4 | 134 | Fudan UniversityOTHER | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06654830 | RATT Vs. VATT for Early-stage TETs | not yet recruiting | Phase 2 | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06665087 | CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC | not yet recruiting | Phase 2 | 110 | Fudan UniversityOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06665841 | Correlation Between Selenium Levels in Human Tissues and HPV-related Cervical Lesions and Outcomes(SeHPV) | not yet recruiting | — | 200 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06666166 | SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer | not yet recruiting | Phase 2 | 28 | Yunpeng LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06662669 | YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Oct 29, 2024 | clinicaltrials |
| NCT06662708 | Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer | not yet recruiting | N/A | 200 | Shao PengfeiOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06662877 | Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment | not yet recruiting | Phase 2 / Phase 3 | 206 | Sun Yat-sen UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06663748 | ARX788 in HER2-positive Metastatic Breast Cancer Patients | not yet recruiting | Phase 2 | 44 | Henan Cancer HospitalOTHER_GOV | 0 | Oct 29, 2024 | clinicaltrials |
| NCT06652412 | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC | not yet recruiting | Phase 2 | 124 | Fudan UniversityOTHER | 0 | Oct 28, 2024 | clinicaltrials |
| NCT06661577 | An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions. | not yet recruiting | — | 3,000 | University of Auckland, New ZealandOTHER | 1 | Oct 28, 2024 | clinicaltrials |
| NCT06658587 | A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma | not yet recruiting | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06658938 | Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation | not yet recruiting | N/A | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT06659770 | A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma | not yet recruiting | — | 200 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Oct 26, 2024 | clinicaltrials |
| NCT06656091 | A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 450 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 0 | Oct 24, 2024 | clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT06657027 | Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma(ARTPLAN-GLIO) | not yet recruiting | — | 40 | Hospital del Rio HortegaOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT05897658 | Levetiracetam Prophylaxis in Brain Tumor Resection Pilot(LeviTaTe Pilot) | not yet recruiting | Phase 3 | 70 | Hamilton Health Sciences CorporationOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06650709 | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study(NEOCATS) | not yet recruiting | Phase 2 | 40 | British Columbia Cancer AgencyOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06655519 | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | not yet recruiting | Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06652139 | Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive | not yet recruiting | Phase 2 | 82 | Ruijin HospitalOTHER | 0 | Oct 22, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Nov 12, 2024source: clinicaltrials